Many thanks for supporting my social media in March. I remain keen to hear any suggestions of the sort of thing you would like me to research and publish. I am working on two or three more blog posts due to come in in the next 10 days, please stay tuned.
The top 10 most-read posts in March are listed below:
A story of strength and inspiration in the most trying of circumstances. Miranda and her parents are determined to help others despite the loss of Miranda. Click here or on the picture.
I turned it back on for a change of scenery. Click the picture or click here.
A surprising entry but clearly something that interests people. Click here or on the picture.
If you need a catch-up, this is the place to go. It updates what is being read most on my website in the last 48 hours and automatically updates. No surprises on its inclusion, I do market it a lot.
Click here or on the picture to read more.
A frequently visited post, very helpful I’m told. It will one day be my most-read blog post. Click here or on the picture
The dangers of the internet. Click here or on the picture.
This was my final newsletter in this format, newsletters now arrive outside of my blog in a new app based on a subscription. Click here or on the picture to read more.
This is such a powerful message; it is popular every time I post it. Click here or on the picture to read more.
Did you miss it, many different posts appeared than are in here. Click here or on the picture to read more.
He may not have generated a lot of awareness for Neuroendocrine Cancer at diagnosis, but this post has been read 30,000 times since I published it. It helps dilute the incorrect info. Click here or on the picture to read more.
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted. Please check any references attached.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards
Vitamin D deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) — but that does not automatically mean your deficiency is caused by
Words are very important to cancer patients, some people hang their hats on them and put their feet up, and some people google them until
Overview Many thanks for the support in January and February 2026. This is a double month newsletter due to my 27 day holiday! 2026 Blog
Vitamin B12 deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) – what that means is there is a chance your deficiency as
When I was a young lad, I didn’t seem to have a fear of heights, not that I got many chances to test it but
When I was diagnosed with metastatic Neuroendocrine Cancer in 2010, there’s a lot of milestones I doubted I would reach. One is today and I
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose
Long-axial field-of-view (LAFOV) systems have changed the field of molecular imaging. Since their introduction, many PET centres have installed these next-generation digital systems to provide
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumours and Other Somatostatin Receptor 2-Expressing Tumours Read the
Subscribe to get the latest posts sent to your email.
